Cynata Therapeutics Ltd has released a press release.
Appendix 4E & Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- At-the-Market Subscription Agreement
- June 2025 Quarterly Activity Report and Appendix 4C
- CYP-001s FDA Approval Pathway Not Impeded
- March 2025 Quarterly Activity Report and Appendix 4C
- Publication comparing Cymerus MSCs to other MSCs
Later from Cynata Therapeutics
- September 2025 Quarterly Activity Report and Appendix 4C
- Cynata Receives $1.7m R&D Tax Incentive Refund
- Final Patient Visit Complete in Phase 3 Osteoarthritis Trial
- Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
- Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics